Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029328 · ClinicalTrials.gov registry record · Phase 1
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
A Phase 1 study, sponsored by FDA Office of Orphan Products Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00029328 is a Phase 1 study that has completed, run by FDA Office of Orphan Products Development. The registered enrollment target is 15 participants.
The verdict
NCT00029328, a Phase 1 study, has completed, sponsored by FDA Office of Orphan Products Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation.
Interventions
- DRUG etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029328
The ClinicalTrials.gov registry entry for NCT00029328 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FDA Office of Orphan Products Development, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which etanercept is the first listed.
NCT00029328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00029328 about?
NCT00029328 is a clinical study titled "Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation". The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation.
What is the current status of trial NCT00029328?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2001-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00029328?
The interventions under investigation include: etanercept (DRUG).
Who is sponsoring clinical trial NCT00029328?
This trial is sponsored by FDA Office of Orphan Products Development, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.